Navigate by Shearman & Sterling LLP | Tools for emerging growth companies
This links to the home page



Ibere Pharmacueticals’ $138 million IPO

Shearman & Sterling advised Ibere Pharmaceuticals, a blank check company formed for the purpose of effecting a merger in the pharmaceutical and life sciences industries, in its $138 million initial public offering.

Read the press release.